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Impact of High-Dose Statin Pretreatment in Patients with Stable 
Angina during Off-Pump Coronary Artery Bypass
Young-Nam Youn, M.D.*, Seong-Yong Park, M.D.*, Yoohwa Hwang, M.D.*, 
Huyn-Chul Joo, M.D.*, Kyung-Jong Yoo, M.D.*
Background: Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic ef-
fects, such as anti-thrombotic and anti-inflammatory actions. We aimed to assess the efficacy of high-dose rosuvas-
tatin loading in patients with stable angina undergoing off-pump coronary artery bypass grafting (OPCAB). Materials 
and Methods: A total of 142 patients with stable angina who were scheduled to undergo surgical myocardial re-
vascularization were randomized to receive either pre-treatment with 60-mg rosuvastatin (rosuvastatin group, n=71) 
or no pre-treatment (control group, n=71) before OPCAB. The primary endpoint was the 30-day incidence of major 
adverse cardiac events (MACEs). The secondary endpoint was the change in the degree of myocardial ischemia 
as evaluated with creatine kinase-myocardial band (CK-MB) and troponin T (TnT). Results: There were no sig-
nificant intergroup differences in preoperative risk factors or operative strategy. MACEs within 30 days after OPCAB 
occurred in one patient (1.4%) in the rosuvastatin group and four patients (5.6%) in the control group, respectively 
(p=0.37). Preoperative CK-MB and TnT were not different between the groups. After OPCAB, the mean maximum 
CK-MB was significantly higher in the control group (rosuvastatin group 10.7±9.75 ng/mL, control group 14.6±12.9 
ng/mL, p=0.04). Furthermore, the mean levels of maximum TnT were significantly higher in the control group 
(rosuvastatin group 0.18±0.16 ng/mL, control group 0.39±0.70 ng/mL, p=0.02). Conclusion: Our findings suggest 
that high-dose rosuvastatin loading before OPCAB surgery did not result in a significant reduction of 30-day 
MACEs. However, high-dose rosuvastatin reduced myocardial ischemia after OPCAB.
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INTRODUCTION
  Reduction of plasma cholesterol, particularly cholesterol 
transported in low-density lipoproteins (LDL), lowers the risk 
of primary and secondary cardiovascular events. 3-hy-
droxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, com-
monly known as statins, can produce significant reductions in 
cholesterol. It is well known that the beneficial effect of sta-
tins on coronary events is related to their hypocholesterolemic 
properties. However, the immediate product of HMG-CoA re-
ductase, mevalonic acid, is not only a substrate for cholester-
ol synthesis but also a precursor of isoprenoids and other me-
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tabolites involved in different cellular pathways of athero-
genesis and thrombosis [1]. As a consequence, statins may 
result in pleiotropic effects that are independent of cholesterol 
reduction, which may explain many of the direct anti-athero-
sclerotic and anti-thrombotic properties of these compounds 
[1-6].
  The ARMYDA (Atorvastatin for Reduction of Myocardial 
Damage During Angioplasty) trial [7] has shown that a 7-day 
pretreatment with atorvastatin is associated with an 81% re-
duction in the risk of periprocedural myocardial infarction in 
patients with stable angina undergoing elective percutaneous 
coronary intervention (PCI). Attenuation of endothelial activa-
tion may explain this protective role at least in part [8], and 
preprocedural loading with atorvastatin may even improve 
outcomes in patients with acute coronary syndrome under-
going early invasive intervention [9].
  Recently, statins were shown to be independently asso-
ciated with a reduced risk of postoperative mortality in pa-
tients undergoing major, noncardiac vascular surgery [10]. 
Furthermore, preoperative statin therapy has been in-
dependently associated with a significant reduction in the risk 
of all-cause mortality in patients undergoing coronary artery 
bypass grafting (CABG) surgery [11-13]. However, patients 
were treated with different types of statins and variable doses, 
and the duration of previous treatment was unknown. 
Additionally, these findings have not been validated in a 
randomized trial, and most patients in these studies underwent 
CABG using cardiopulmonary bypass. 
  Avoiding the systemic inflammatory response that may re-
sult from cardiopulmonary bypass, off-pump coronary bypass 
grafting (OPCAB) is known to have benefits in high-risk 
patients. The anti-inflammatory and pleiotropic effects of sta-
tins and their effects on clinical outcomes for patients who 
undergo the OPCAB procedure have not been described. The 
aim of the current study was to determine whether pre-
operative rosuvastatin loading is independently associated 
with reduced myocardial ischemia and clinical outcomes in 
patients with stable angina undergoing isolated OPCAB.
MATERIALS AND METHODS
1) Study population and design
  This trial was a single-center, randomized, prospective trial 
performed at our hospital. Inclusion criteria were the presence 
of stable angina, age between 18 and 80 years, and a need 
for isolated surgical myocardial revascularization. Exclusion 
criteria were evidence of recent myocardial infarction and un-
stable angina, emergent or urgent operation, history of prior 
cardiac surgery, any increase in liver enzymes, renal failure 
with serum creatinine ＞3 mg/dL, left ventricular ejection 
fraction ＜35%, and history of liver or muscle disease. From 
October 2007 to December 2008, a total of 214 patients who 
met the inclusion criteria were initially evaluated; 7 patients 
were excluded because of previous cardiac surgery, 15 for in-
creased liver enzymes, 16 for renal failure with creatinine >3 
mg/dL, 19 for low ejection fraction, 5 for history of liver dis-
ease, and 10 for refusal to participate in the study. Eligible 
patients (n=142) were randomized to receive rosuvastatin (40 
mg loading dose 12 hours before surgery and a second 20 
mg dose 2 hours before surgery) or no pretreatment (control 
group). Patients were assigned in a 1 : 1 ratio using a com-
puter-generated randomization sequence. This study protocol 
was approved by the Institutional Review Board of Yonsei 
University College of Medicine and individual patient consent 
was obtained.
2) Operative technique 
  We have previously described the operative technique and 
graft strategy [14,15]. The operation was performed through a 
full sternotomy incision or minimal incision through the left 
fifth intercostal space, and the left internal mammary artery 
was harvested in a semi-skeletonized fashion. The second 
choice of graft was the radial artery, which was harvested 
with a harmonic scalpel (Ethicon Endosurgery Inc., Cincinna-
ti, OH). The right internal mammary artery, saphenous vein, 
or right gastroepiploic artery was also harvested if necessary. 
Heparin (0.7∼1.0 mg/kg) was administered to achieve a tar-
get activated clotting time (≥300 seconds) before ligation of 
the distal internal mammary artery. Target arteries were stabi-
lized with a tissue stabilizer and heart positioner. During 
anastomosis, blood was removed from the arteriotomy sites 
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Table 1. Demographics and baseline clinical characteristics
　 Rosuvastatin 
group
Control 
group
p-value
Female 
Age, yrs 
Smoker 
Diabetes mellitus 
Hypertension 
Dyslipidemia 
Chronic statin treatment 
Chronic renal failure
CVA history 
PAOD 
Previous PTCA 
Preoperative medication 
  Beta blocker 
  ACE inhibitor
  IV Nitrate 
  ARB
Old myocardial infarction
Three vessel disease
Left main disease
Ejection fraction (%) 
EuroSCORE 
14 (19.7)
65.9±8.6
34 (47.9)
28 (39.4)
52 (73.2)
20 (28.2)
39 (54.9)
 9 (12.7)
 9 (12.7)
 8 (11.3)
10 (14.1)
51 (71.8)
7 (9.9)
22 (31)
21 (29.6)
21 (29.6)
58 (81.7)
24 (33.8)
59.6±13.8
3.1±2.2
18 (25.4)
66.6±7.6
39 (54.9)
31 (43.7)
54 (76.1)
20 (28.2)
39 (54.9)
6 (8.5)
4 (5.6)
2 (2.8)
 9 (12.7)
48 (67.6)
 9 (12.7)
17 (23.9)
22 (31)
23 (32.4)
63 (88.7)
21 (29.6)
59.5±16.0
3.3±2.1
0.42 
0.62
0.40 
0.61 
0.70 
1.00 
1.00 
0.41 
0.24 
0.10 
0.81 
0.58 
0.60 
0.35 
0.86 
0.72 
0.43 
0.59 
0.95 
0.53 
CVA=Cerebrovascular accident; PAOD=Peripheral artery obstr-
uctive disease; PTCA=Percutaneous transluminal coronary angi-
oplasty; ACE=Angiotensin converting enzyme; IV=Intravenous; 
ARB=Angiotensin II receptor blocker; EuroSCORE=European 
system for cardiac operative risk evaluation.
with a misted carbon dioxide blower and irrigation with 
warm saline. After surgery, patients were transferred to the 
intensive care unit and managed as usual.
3) Cardiac enzyme assay
  In all patients, blood samples were collected before 
OPCAB and at 24, 48, and 72 hours after OPCAB to de-
termine the levels of creatine kinase-myocardial band 
(CK-MB) isoenzyme and troponin-T. Normal limits of 
CK-MB and troponin T were defined as ≤5 ng/mL and 
＜0.1 μg/L, respectively. 
4) Data collection and definition of terms
  Preoperative, intraoperative, and postoperative data were 
collected prospectively from the registry database, medical 
notes, and medical charts. Detailed data were collected on the 
admission when cardiac surgery was performed. Complete re-
vascularization was defined as the placement of at least one 
graft onto each of the three major vascular regions that ex-
hibited stenosis of more than 50% of diameter [16,17]. 
Perioperative MI was defined as an increase in biomarkers 
greater than 5 times the 99th percentile of the upper reference 
limit (URL) plus one of the following: either new patho-
logical Q waves or new LBBB, angiographically documented 
new graft or native coronary artery occlusion, or imaging evi-
dence of new loss of viable myocardium [18]. Other variables 
were defined according to the Society of Thoracic Surgeons 
Adult Cardiac Database Definition of Terms version 2.61 
(http://www.sts.org/documents/pdf/AdultCVDataSpecifications2. 
61.pdf). 
5) Endpoints
  The primary endpoint was the occurrence of major adverse 
cardiac events (MACEs), which included the following: death 
from all causes, non-fatal myocardial infarction (MI), and re-
peat revascularization by percutaneous intervention or bypass 
surgery within 30 days after the operation. The secondary 
endpoint was the difference in the degree of myocardial is-
chemia between the two groups after OPCAB. The degree of 
myocardial ischemia was measured by the highest level of 
cardiac enzymes after OPCAB. 
6) Statistical analysis
  Categorical variables were expressed as mean±standard de-
viation (SD). Categorical variables were compared by χ2 test 
or Fisher’s exact test. A Student’s t-test was used to compare 
continuous variables for normal distribution; otherwise, the 
Mann-Whitney U test was used. Data were analyzed using 
SPSS for Windows, version 15.0 (SPSS, Inc, Chicago, IL). 
p-values equal to or less than 0.05 indicated a significant dif-
ference, and all p-values were two-tailed.
RESULTS
  Seventy-one patients were allocated to each group. Patient 
demographics and baseline clinical characteristics are dis-
played in Table 1. The two groups were similar in regards to 
the following: age; prevalence of females; smoking status; 
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Table 2. Operative data
　 Rosuvastatin 
group
Control 
group
p-value
Operation time (min) 
Distal anastomosis 
Total arterial grafting
Use of LITA
Complete revasculazation 
235.3±39.9
3.2±0.8
37 (52.1)
70 (98.6)
71 (100)
240.5±39.6
3.1±0.8
44 (62.0)
69 (97.2)
69 (97.2)
0.34
0.4
0.24
1.00 
0.5
LITA=Left internal thoracic artery.
Table 3. Incidence of the primary endpoint
　 Rosuvastatin 
group
Control 
group
p-value
30-day MACEs
Death
Nonfatal MI
Target vessel 
 revascularization
1 (1.4)
0
0
1 (1.4)
4 (5.6)
1 (1.4)
3 (4.2)
0
0.37
1
0.25
1
MACEs=Major adverse cardiac events; MI=Myocardial infarc-
tion.
Fig. 1. Changes in cardiac enzymes after operation. (A) Change in the level of CK-MB. (B) Change in the level of troponin T. 
Preop=Preoperative level (white bar); Highest=Highest level at postoperative period (gray bar). *=p-value＜0.05.
prevalence of diabetes mellitus, hypertension, dyslipidemia 
chronic renal failure, and peripheral arterial obstructive dis-
ease; chronic statin treatment for more than one month; his-
tory of cerebrovascular accidents and percutaneous trans-
luminal coronary angioplasty; medication use; degree of coro-
nary artery disease; and left ventricular ejection fraction. 
Preoperative risk, as assessed by EuroSCORE, was not sig-
nificantly different between the groups (rosuvastatin group 
3.1±2.2, control group 3.3±2.1, p=0.53). There were no sig-
nificant differences in the duration of the operation, number 
of distal anastomosis, total arterial grafting, or complete re-
vascularization (Table 2).
  The primary endpoint was evaluated at 30 days (Table 3). 
The composite primary endpoint of death, myocardial in-
farction, and target vessel revascularization occurred in 3.5% 
of patients (5 of 142), one patient (1.4%) in the rosuvastatin 
group and four patients (5.6%) in the control group. No sig-
nificant difference was found between groups in overall 
(p=0.37) or individual cardiac events. One patient with chron-
ic renal failure died in the control group due to the ag-
gravation of renal and respiratory failure.
  Changes in cardiac enzymes are displayed in Fig. 1. 
Preoperative CK-MB and troponin T were not different be-
tween groups (CK-MB, rosuvastatin group 2.15±0.85 ng/mL, 
control group 1.99±0.76 ng/mL, p=0.24; troponin T, rosuvas-
tatin group 0.03±0.07 ng/mL, control group 0.03±0.09 
ng/mL, p=0.52). After OPCAB, the mean maximum CK-MB 
was significantly higher in the control group (rosuvastatin 
group 10.7±9.75 ng/mL, control group 14.6±12.9 ng/mL, 
p=0.04). Furthermore, the levels of the mean maximum tropo-
nin T were significantly higher in the control group 
(rosuvastatin group 0.18±0.16 ng/mL, control group 
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0.39±0.70 ng/mL, p=0.02). In the rosuvastatin group, CK-MB 
decreased by 26.7% and troponin T decreased by 53.8% 
compared to the control group.
DISCUSSION
  This study is the first single-center randomized trial to 
evaluate the efficacy of high-dose rosuvastatin loading (60 
mg) before OPCAB in patients with stable angina. At the 
1-month clinical follow-up assessment, the occurrence of ma-
jor cardiac events was not significantly different between the 
control and 60-mg rosuvastatin pretreatment groups. However, 
our study suggests that high-dose rosuvastatin loading before 
OPCAB may decrease myocardial ischemia as determined by 
CK-MB and troponin T after OPCAB.
  The benefit of periprocedural treatment with statins in 
on-pump CABG is well established. In the Multicenter Study 
of Perioperative Ischemia (McSPI) Epidemiology II Study 
[13], the authors reported that preoperative statin therapy was 
independently associated with a significant reduction in the 
risk of early cardiac death after elective on-pump CABG, but 
was not associated with a reduced risk of postoperative non-
fatal, in-hospital MI. Powell et al. [19] evaluated the influ-
ence of lipid-lowering therapy for 30 days before CABG. In 
this observational study with 4,739 patients, in-hospital mor-
tality was significantly lower in the lipid-lowering therapy 
group than in the nonlipid-lowering therapy group (1.4% vs. 
2.2%, odds ratio 0.62, 95% CI 0.40∼0.96, p=0.03). Even 
though the multivariable model demonstrated a loss of stat-
istical significance for the effect of lipid-lowering therapy on 
in-hospital mortality, they suggested that patient risk factors 
and the use of other cardioprotective medications associated 
with the use of preoperative lipid-lowering therapy appeared 
to explain the association with improved survival. Several 
prospective trials have been conducted to validate these find-
ings of statin pre-treatment in PCI and CABG settings. In the 
ARMYDA-ACS trial [9], short-term atorvastatin loading con-
ferred an 88% risk reduction in 30-day MACEs in patients 
with acute coronary syndrome before PCI. Mannacio et al. 
evaluated the effect of 20 mg/d rosuvastatin pretreatment for 
1 week before on-pump CABG. Troponin I, myoglobin, and 
CK-MB mass values were assessed, and all biological mark-
ers were significantly lower in the rosuvastatin pretreatment 
group. However, few studies have evaluated statin pretreat-
ment in OPCAB patients. Song et al. [20] reported that pre-
operative loading with atorvastatin for 3 days before OPCAB 
significantly reduced the occurrence of postoperative atrial 
fibrillation.
  A total of 60 mg rosuvastatin was loaded before OPCAB 
in this study. According to a well-reviewed paper [21] about 
pre-procedural statin therapy, the loading dosages of various 
statins before PCI or CABG were mostly determined by 
researchers. In our preliminary study, 40 mg rosuvastatin 
loading 12 hours before OPCAB did not result in significant 
decreases of cardiac enzymes and inflammatory markers. 20 
mg of rosuvastatin were added 2 hours before OPCAB, and 
no serious side effects of 60 mg rosuvastatin loading were 
found.
  This study found no significant reduction in 30-day 
MACEs. The effects of high-dose rosuvastatin loading in this 
study could not be determined because the incidence of clin-
ical events was low in both patient groups. However, there 
was a tendency toward a lower number of MACEs in the ro-
suvastatin loading group and further study with more patients 
is warranted.
  In this study, statin loading before OPCAB significantly 
lowered the degree of myocardial ischemia as assessed by 
cardiac enzymes. Although these beneficial effects of statin 
loading on myocardial protection cannot be completely ex-
plained, this early protective effect of statins is unlikely to be 
the result of its effect on cholesterol. Instead, statins exert 
pleiotropic effects that may be initiated before its lipid-low-
ering effects [22]. Previous studies show the improvement of 
myocardial ischemia after OPCAB that we observed in this 
study. Protection from aggravation of myocardial ischemia 
may result from the pleiotropic effects of statins, such as the 
improvement of endothelial function, dilatation of coronary 
microvessels, anti-thrombotic effects, and anti-inflammatory 
action [23,24]. 
  Our study had several limitations. First, two surgeons from 
a single center conducted the trial. Second, myocardial ische-
mia was only assessed by CK-MB and troponin T, which 
may have lower specificity in certain conditions, such as re-
nal dysfunction. Third, sample size was relatively small with 
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low clinical morbidity and mortality, and accordingly, a stat-
istical difference may not have been detected. These factors 
should be addressed using larger cohorts in multicenter trials 
that evaluate the effects of statin loading before OPCAB 
surgery. 
CONCLUSION
  Our findings suggest that high-dose rosuvastatin loading 
before OPCAB surgery did not result in a significant reduc-
tion of 30-day MACEs. However, high-dose rosuvastatin re-
duced myocardial ischemia after OPCAB.  
REFERENCES
1. Goldstein JL, Brown MS. Regulation of the mevalonate 
pathway. Nature 1990;343:425-30.
2. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. 
Requirement for mevalonate in acetylated LDL induction of 
cholesterol esterification in macrophages. Atherosclerosis 
1993;104:19-26.
3. Corsini A, Mazzotti M, Raiteri M, et al. Relationship be-
tween mevalonate pathway and arterial myocyte pro-
liferation: in vitro studies with inhibitors of HMG-CoA 
reductase. Atherosclerosis 1993;101:117-25.
4. Grunler J, Ericsson J, Dallner G. Branch-point reactions in 
the biosynthesis of cholesterol, dolichol, ubiquinone and pre-
nylated proteins. Biochimica et Biophysica Acta 1994;1212: 
259-77.
5. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, 
Paoletti R. Pathogenesis of atherosclerosis and the role of 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 
Am J Cardiol 1995;76:21A-8A.
6. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, 
Corsini A. Pleiotropic effects of statins in atherosclerosis 
and diabetes. Diabetes Care 2000;23(Suppl 2):B72-8.
7. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di 
Sciascio G. Randomized trial of atorvastatin for reduction of 
myocardial damage during coronary intervention: results 
from the ARMYDA (Atorvastatin for Reduction of 
MYocardial Damage during Angioplasty) study. Circulation 
2004;110:674-8.
8. Patti G, Chello M, Pasceri V, et al. Protection from proce-
dural myocardial injury by atorvastatin is associated with 
lower levels of adhesion molecules after percutaneous coro-
nary intervention: results from the ARMYDA-CAMs 
(Atorvastatin for Reduction of MYocardial Damage during 
Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll 
Cardiol 2006;48:1560-6.
9. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreat-
ment improves outcomes in patients with acute coronary syn-
dromes undergoing early percutaneous coronary inter-
vention: results of the ARMYDA-ACS randomized trial. J 
Am Coll Cardiol 2007;49:1272-8.
10. Poldermans D, Bax JJ, Kertai MD, et al. Statins are asso-
ciated with a reduced incidence of perioperative mortality in 
patients undergoing major noncardiac vascular surgery. 
Circulation 2003;107:1848-51.
11. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard 
CD. Statins are associated with a reduced incidence of peri-
operative mortality after coronary artery bypass graft 
surgery. Circulation 2004;110:II45-9.
12. Clark LL, Ikonomidis JS, Crawford FA Jr, et al. Preoper-
ative statin treatment is associated with reduced post-
operative mortality and morbidity in patients undergoing 
cardiac surgery: an 8-year retrospective cohort study. J 
Thorac Cardiovasc Surg 2006;131:679-85.
13. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT. 
Preoperative statin therapy is associated with reduced car-
diac mortality after coronary artery bypass graft surgery. J 
Thorac Cardiovasc Surg 2006;132:392-400.
14. Youn YN, Kwak YL, Yoo KJ. Can the EuroSCORE predict 
the early and mid-term mortality after off-pump coronary ar-
tery bypass grafting? Ann Thorac Surg 2007;83:2111-7.
15. Yang H, Youn YN, Yoo KJ. Correlation of akinesia with 
graft patency and cardiac enzyme after off-pump coronary 
artery bypass graft surgery. Circ J 2010;74:1564-9.
16. Vander Salm TJ, Kip KE, Jones RH, et al. What constitutes 
optimal surgical revascularization? Answers from the Bypass 
Angioplasty Revascularization Investigation (BARI). J Am 
Coll Cardiol 2002;39:565-72.
17. Sabik JF, Blackstone EH, Lytle BW, Houghtaling PL, 
Gillinov AM, Cosgrove DM. Equivalent midterm outcomes 
after off-pump and on-pump coronary surgery. J Thorac 
Cardiovasc Surg 2004;127:142-8.
18. Thygesen K, Alpert JS, White HD. Universal definition of 
myocardial infarction. J Am Coll Cardiol 2007;50:2173-95.
19. Powell BD, Bybee KA, Valeti U, et al. Influence of pre-
operative lipid-lowering therapy on postoperative outcome in 
patients undergoing coronary artery bypass grafting. Am J 
Cardiol 2007;99:785-9.
20. Song YB, On YK, Kim JH, et al. The effects of atorvastatin 
on the occurrence of postoperative atrial fibrillation after 
off-pump coronary artery bypass grafting surgery. Am Heart 
J 2008;156:373 e9-16.
21. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of 
pre-procedural statin therapy a meta-analysis of randomized 
trials. J Am Coll Cardiol 2010;56:1099-109.
22. Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, 
Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coen-
zyme a reductase inhibition on coronary endothelial function. 
Young-Nam Youn, et al
− 214 −
Circ Res 2003;93:e98-103.
23. Hinoi T, Matsuo S, Tadehara F, Tsujiyama S, Yamakido M. 
Acute effect of atorvastatin on coronary circulation measured 
by transthoracic Doppler echocardiography in patients with-
out coronary artery disease by angiography. Am J Cardiol 
2005;96:89-91.
24. Ray KK, Cannon CP. Early time to benefit with intensive 
statin treatment: could it be the pleiotropic effects? Am J 
Cardiol 2005;96:54F-60F.
